LENTI-D
Live / Registered — Registered — Section 71 accepted (as of 07 Feb 2025)
What this means for you
Registered since 13 Nov 2018. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 13 Nov 2028: the §71 ten-year affidavit of use).
Record
- Serial number
- 79232103
- Registration number
- 5603940
- Mark type
- Word mark
- Filed
- 15 Mar 2018
- Published for opposition
- 28 Aug 2018
- Registered
- 13 Nov 2018
- Next maintenance filing
- §71 ten-year affidavit of use, due by 13 Nov 2028 (grace period to 13 May 2029)
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of genetic diseases
Owner
- Genetix Biotherapeutics Inc., US
- Genetix Biotherapeutics, Inc., US
- bluebird bio, Inc., Somerville, DE, US
- bluebird bio (UK) Ltd., GB
- bluebird bio (UK) Ltd., GB
- bluebird bio (UK) Ltd., GB
Prosecution history
- 24 Sept 2026 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 18 Dec 2025 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 13 Nov 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 07 Feb 2025 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 07 Feb 2025 — REGISTERED-SEC.71 ACCEPTED
- 30 Dec 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 13 Sept 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 29 May 2024 — TEAS SECTION 71 RECEIVED
- 23 Dec 2023 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 13 Nov 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 26 Aug 2022 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 15 Nov 2019 — NEW REPRESENTATIVE AT IB RECEIVED
- 18 Oct 2019 — NEW REPRESENTATIVE AT IB RECEIVED
- 13 Jun 2019 — CHANGE OF OWNER RECEIVED FROM IB
- 16 Mar 2019 — FINAL DECISION TRANSACTION PROCESSED BY IB